{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:25:56Z","timestamp":1790724356506,"version":"4.1.0"},"reference-count":70,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,11,26]],"date-time":"2016-11-26T00:00:00Z","timestamp":1480118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"the National Health and Medical Research Council of Australia"},{"name":"the Cancer Council of Victoria"},{"DOI":"10.13039\/100005189","name":"the Leukemia and Lymphoma Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Victorian Cancer Agency"},{"DOI":"10.13039\/501100000947","name":"the Australian Cancer Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000947","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:p>The intracellular protein B\u2010cell\u2010lymphoma\u20102 (BCL2) has been considered an attractive target for cancer therapy since the discovery of its function as a major promoter of cell survival (an anti\u2010apoptotic) in the late 1980s. However, the challenges of targeting a protein\u2010protein interaction delayed the discovery of fit\u2010for\u2010purpose molecules until the mid\u20102000s. Since then, a series of high affinity small organic molecules that inhibits the interaction of BCL2 with the apoptotic machinery, the so\u2010called BH3\u2010mimetics, have been developed. Venetoclax (formerly ABT\u2010199) is the first to achieve US Food and Drug Administration approval, with an indication for treatment of patients with previously treated chronic lymphocytic leukemia (CLL) bearing deletion of the long arm of chromosome 17. Here, we review key aspects of the science underpinning the clinical application of BCL2 inhibitors and explore both our current knowledge and unresolved questions about its clinical utility, both in CLL and in other B\u2010cell malignancies that highly express BCL2.<\/jats:p>","DOI":"10.1002\/cpt.553","type":"journal-article","created":{"date-parts":[[2016,11,26]],"date-time":"2016-11-26T04:26:47Z","timestamp":1480134407000},"page":"89-98","source":"Crossref","is-referenced-by-count":133,"title":["Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies"],"prefix":"10.1111","volume":"101","author":[{"given":"AW","family":"Roberts","sequence":"first","affiliation":[{"name":"Integrated Department of Clinical Hematology The Royal Melbourne Hospital and Peter MacCallum Cancer Centre Parkville Australia"},{"name":"Cancer and Haematology Division Walter and Eliza Hall Institute of Medical Research Parkville Australia"},{"name":"Faculty of Medicine, Dentistry, and Health Sciences The University of Melbourne Parkville Australia"},{"name":"Victorian Comprehensive Cancer Centre Parkville Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DCS","family":"Huang","sequence":"additional","affiliation":[{"name":"Cancer and Haematology Division Walter and Eliza Hall Institute of Medical Research Parkville Australia"},{"name":"Faculty of Medicine, Dentistry, and Health Sciences The University of Melbourne Parkville Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,11,26]]},"reference":[{"key":"e_1_2_6_1_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.3874430"},{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/335440a0"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(89)90174-8"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/348331a0"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc883"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1101\/sqb.2005.70.009"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2011.307"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2004.12.030"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.2174\/156652408783769599"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506654102"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-173310"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.569962"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0730"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.151"},{"key":"e_1_2_6_15_1","first-page":"e302","article-title":"Resistance to ABT\u2010199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors","volume":"100","author":"Thijssen R.","year":"2015","journal-title":"Haematologica"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.1.244"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05954.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2004.04.018"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206297"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.43"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.1254"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0955"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-704908"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.216"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2527"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.8.2986"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-707414"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-026500"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-284968"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2658"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2006.08.027"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.0981"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2014.05.008"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5292.1531"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03579"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI28281"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5836"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm800669s"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70261-8"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.7898"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.01.037"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4402072"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3048"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12457"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513257"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-688796"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30019-5"},{"key":"e_1_2_6_48_1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1182\/blood.V126.23.254.254","article-title":"A phase 1 study of venetoclax (ABT\u2010199 \/ GDC\u20100199) monotherapy in patients with relapsed\/refractory non\u2010Hodgkin lymphoma","volume":"126","author":"Gerecitano J.F.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_6_49_1","first-page":"58","article-title":"Durable treatment\u2010free remission and effective retreatment in patients with relapsed\/refractory chronic lymphocytic leukemia who achieved a deep response with venetoclax combined with rituximab","volume":"101","author":"Brander D.","year":"2016","journal-title":"Haematologica"},{"key":"e_1_2_6_50_1","doi-asserted-by":"crossref","first-page":"7527","DOI":"10.1200\/JCO.2016.34.15_suppl.7527","article-title":"Safety, efficacy and immune effects of venetoclax 400 mg daily in patients with relapsed chronic lymphocytic leukemia (CLL)","volume":"34","author":"Davids M.S.","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa4642"},{"key":"e_1_2_6_52_1","doi-asserted-by":"crossref","first-page":"8032","DOI":"10.1200\/JCO.2016.34.15_suppl.8032","article-title":"Phase 1 study of venetoclax monotherapy for relapsed\/refractory multiple myeloma","volume":"34","author":"Kumar S.","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-400929"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2297"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.525"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0809957105"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0606176103"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2809"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3275"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.350"},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-475855"},{"key":"e_1_2_6_62_1","first-page":"81","article-title":"Phase 1b study of venetoclax combined with bortezomib and dexamethasone in relapsed\/refractory multiple myeloma","volume":"101","author":"Moreau P.","year":"2016","journal-title":"Haematologica"},{"key":"e_1_2_6_63_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1030638"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13487"},{"key":"e_1_2_6_65_1","first-page":"51","article-title":"Impact of adding rituximab to venetoclax on the rate, quality, and duration of response in patients with relapsed\/refractory chronic lymphocytic leukaemia: a cross\u2010study multivariable analysis","volume":"101","author":"Roberts A.W.","year":"2016","journal-title":"Haematologica"},{"key":"e_1_2_6_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-014-0116-3"},{"key":"e_1_2_6_67_1","first-page":"103","article-title":"The combination of ibrutinib and venetoclax (Abt\u2010199) rapidly achieves complete remissions in patients with relapsed\/refractory mantle cell lymphoma: preliminary results of the phase II aim study","volume":"101","author":"Tam C.","year":"2016","journal-title":"Haematologica"},{"key":"e_1_2_6_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.561"},{"key":"e_1_2_6_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.184"},{"key":"e_1_2_6_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature19830"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt.553","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.553","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T08:34:53Z","timestamp":1699346093000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,26]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1002\/cpt.553"],"URL":"https:\/\/doi.org\/10.1002\/cpt.553","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,26]]}}}